Hiva Fassihi

Hiva Fassihi

Auto-generated profile, based on publicly available information

Hiva Fassihi

Photodermatology Unit, St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust , London

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AYAndrey A. Yurchenko
Andrey A. Yurchenko
FRFatemeh Rajabi
Fatemeh Rajabi
TBTirzah Braz-Petta
Tirzah Braz-Petta
HFHiva Fassihi
Hiva Fassihi
ALAlan Lehmann
Alan Lehmann
SNSergey Nikolaev
Sergey Nikolaev
Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) or in Translesion Synthesis DNA polymerase η (V). XP is associated with an increased skin cancer risk, reaching, for some groups, several thousand-fold compared to the general population. Here, we analyze 38 skin cancer genomes from five XP groups. We find that the activity of NER determines heterogeneity of the mutation rates across skin cancer genomes and that transcription-coupled NER extends beyond the gene boundaries reducing the intergenic mutation rate. Mutational profile in XP-V tumors and experiments with POLH knockout cell line reveal the role of polymerase η in the error-free bypass of (i) rare TpG and TpA DNA lesions, (ii) 3’ nucleotides in pyrimidine dimers, and (iii) TpT photodimers. Our study unravels the genetic basis of skin cancer risk in XP and provides insights into the mechanisms reducing UV-induced mutagenesis in the general population.

1 September 2022 in British Journal of Dermatology
Verified
Journal Article
Closed access
VGVictoria Goulden
Victoria Goulden
TLTsui C. Ling
Tsui C. Ling
PBParastoo Babakinejad
Parastoo Babakinejad
RDRobert Dawe
Robert Dawe
EEEwan Eadie
Ewan Eadie
OUon behalf of the British Association of Dermatologists’ Clinical Standards Unit
on behalf of the British Association of Dermatologists’ Clinical Standards Unit

1 December 2023 in Brain
Verified
Journal Article
Open access
PDF file
HGHector Garcia-Moreno
Hector Garcia-Moreno
DLDouglas R Langbehn
Douglas R Langbehn
AAAdesoji Abiona
Adesoji Abiona
IGIsabel Garrood
Isabel Garrood
ZFZofia Fleszar
Zofia Fleszar
PGPaola Giunti
Paola Giunti
Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.

22 July 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SGSara Giovannini
Sara Giovannini
LWLisa Weibel
Lisa Weibel
BSBirgit Schittek
Birgit Schittek
TSTobias W. Sinnberg
Tobias W. Sinnberg
MSMartin Schaller
Martin Schaller
MBMark Berneburg
Mark Berneburg

18 April 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
OKOlivia Kuo
Olivia Kuo
KMKevin Molloy
Kevin Molloy
ASAtaf Sabir
Ataf Sabir
AFAndrew Fleming
Andrew Fleming
MEMatthew Edwards
Matthew Edwards
PPPhilip Preston
Philip Preston
Noonan syndrome with multiple lentigines (NSML) is a rare autosomal dominant condition arising from gene variants involved in the RAS-MAPK pathway. The presence of multiple skin cancers is not widely reported in NSML. We report on a novel missense variant causing NSML in a patient with an unusual distribution of lentigines and multiple skin cancers. An increased awareness of the potential for malignant change of lentigines in NSML may encourage regular skin surveillance as a mainstay of multidisciplinary management, enabling early diagnosis and management of skin cancers in this group of patients.

2 January 2026 in Clinical Genetics
Verified
Journal Article
Open access
EBElena Botta
Elena Botta
HFHeather Fawcett
Heather Fawcett
Donata OrioliDonata Orioli
Donata Orioli
HFHiva Fassihi
Hiva Fassihi
ALAlan R. Lehmann
Alan R. Lehmann
Protein truncation mutations in the gene for XPG nuclease cause a very severe clinical phenotype. Two siblings have splicing mutations, which result in in-frame deletions and a less severe phenotype.